Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia
NCT00866073
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
238
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
DRUG:
Decitabine 15 mg/m2 i.v.
Sponsor
University Hospital Freiburg